This site is intended for Great Britain healthcare professionals only 
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

PATIENT PROFILE 2

Middle-aged mother with uncontrolled, severe eczematous lesions, resulting in self-consciousness and anxiety​​​​​​​​​​​​​​


Who is the patient?

This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.​​​​​​​
  • ​​​​​​​Caucasian female, 50 years old
  • Disease and treatment history: AD diagnosed during childhood, recurred in mid-40s with severe eczematous lesions. 4-year treatment journey including topical corticosteroids and TCI, phototherapy, ciclosporin and dupilumab 300 mg Q2W. Some response to dupilumab, but EASI reduction of 50% not achieved after 16 weeks of therapy
  • Clinical assessment: EASI=30; 50% BSA (including the face, neck, torso and arms)
  • Personal impact: Self-conscious about visible lesions around face and arms, resulting in anxiety
  • Preferences: Uneasy about injections; preference for a simple, non-invasive treatment, ideally without the need to use cream/ointment
​​​​​​​

​​​​​​​

Why consider Cibinqo (abrocitinib)?

1. Significantly more patients achieved skin clearance at Week 12 with Cibinqo vs placebo1–4

JADE MONO-1 AND MONO-2 (PRIMARY ENDPOINT)

Proportion of patients achieving EASI-75, MONO-11,2

EASI-75 at Week 12

no./Total no. (%, 95% CI)

Cibinqo 200 mg

96/153 (62.7%; 55.1–70.4)

Cibinqo 100 mg

62/156 (39.7%; 32.1–47.4)

Placebo

9/76 (11.8%; 4.6–19.1)

Proportion of patients achieving EASI-75, MONO-21,3,4

EASI-75 at Week 12

no./Total no. (%, 95% CI)

Cibinqo 200 mg

94/154 (61.0%; 53.3–68.7)

Cibinqo 100 mg

69/155 (44.5%; 36.7–52.3)

Placebo

8/77 (10.4%; 3.6–17.2)

Statistical significance was also achieved for Cibinqo 200 mg and 100 mg vs placebo for the other co-primary endpoint, IGA 0/1 at Week 12 in both JADE MONO-1 and MONO-2.

2. Significantly more patients achieved itch relief with Cibinqo vs placebo1–4

JADE MONO-1 AND MONO-2 (KEY SECONDARY ENDPOINT)

Proportion of patients achieving PP-NRS4, MONO-11,2

Proportion of patients achieving PP-NRS4, MONO-21,3,4

3. Cibinqo provides durable skin clearance1,5

JADE EXTEND (POST HOC ANALYSIS)

EASI-75 at 48 weeks1

Among patients who achieved response after 12 weeks of treatment and entered JADE EXTEND*
Percentage of patients who maintained EASI-75 at Week 48

EASI-75 12 weeks after switching from dupilumab5

Among patients who received dupilumab and did not achieve an EASI-75 response at Week 16 in JADE COMPARE

Data limitations: Not all patients who completed the pivotal studies continued into the long-term extension study. Efficacy improvements seen in this study may be partially due to awareness of receiving active treatment and background medicated topical therapy. Response to Cibinqo 100 mg and 200 mg after previous treatment with dupilumab was assessed as a post-hoc analysis in the sub-set of patients who received dupilumab in JADE COMPARE and completed the study before entering JADE EXTEND.

Biases:​​​​​​​ JADE EXTEND is a parallel treatment assignment study of Cibinqo 200 mg and 100 mg with no placebo control, revealing the certainty of receiving treatment. The lack of placebo control limits the estimate of treatment effect. Due to patients having to complete a qualified parent study and remaining eligible to receive Cibinqo, there may be an enrichment in response based on the patient population.

Explore more

Patient 3

Young professional female with persistent, uncontrolled itching and lesions that are impacting her work.

View profile

Patient 4

Teenage competitive swimmer suffering with regular disease flares and itching.

View profile

This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.

*This analysis included patients who had received Cibinqo in MONO-1, MONO-2, COMPARE and subsequently enrolled in EXTEND, the long-term extension study. Patient was counted as non-responder after withdrawal.
The patient population included is small and therefore no conclusions can be drawn from these data.

AD=atopic dermatitis; BSA=body surface area; CI​​​​​​​=confidence interval; EASI=Eczema Area and Severity Index; IGA=Investigator’s Global Assessment; PP-NRS=Peak Pruritus Numerical Rating Scale; Q2W=once every two weeks; TCI=topical calcineurin inhibitor.
References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics. 2. Simpson E, et al. Lancet 2020;396(10246):255–266. 3. Silverberg J, et al. JAMA Dermatol 2021;156(8):863–873. 4. Silverberg J, et al. JAMA Dermatol 2021; 156(8):863–873. Supplementary appendix. 5. Shi V, et al. Poster #179 presented at: San Diego Dermatology Symposium. 11–13 June 2021.
PP-CIB-GBR-0057. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No